About Lapix Therapeutics
Lapix Therapeutics is a private company based in Cambridge, Massachusetts. It has reported $14,915,924 raised in four offerings on Form D since October 2022.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 21, 2025 | Aug 5, 2025 | $2,200,000of $5.0M target | 10 | $220K | Simple Agreement for Future EquityRule 506(b) | Form D ↗ |
| Aug 2, 2024 | Aug 19, 2024amended Feb 10, 2025 | $5,520,946of $6.0M target | 25 | $220K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Apr 14, 2023 | Apr 27, 2023 | $5,947,478of $14.5M target | 32 | $185K | EquityRule 506(b) | Form D ↗ |
| Aug 29, 2022 | Oct 18, 2022 | $1,247,500of $1.5M target | 7 | $178K | Simple Agreements for Future EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $14,915,924 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Lapix Therapeutics's Form D filed Aug 5, 2025.
AF
Anas Fathallah
President and Secretary, director
AG
Anthony Gibney
Director
JN
Jason Norris
Vice President and Treasurer, director
Francisco Leon
Director
Also a director at Paulex Bio and a founder and CEO, director at Tolerance Bio.
HM
Henry McKinnell
Director